Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsMVP Health Care Hemophilia Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentMVP Health CarePolicy N/A

    Medicare Part B: Hemophilia Gene Therapy

    Customize your policy alerts

    Sign up for all MVP Health Care policy alerts

    Know when MVP Health Care releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs Medicare Part B coverage and prior authorization for the one-time gene therapies Roctavian and Hemgenix under the medical benefit. It applies to members with qualifying severe or moderately severe hemophilia who meet specified diagnostic, laboratory, clinical, and monitoring requirements.

    Policy Summary
    PayerMVP Health Care
    PolicyMedicare Part B: Hemophilia Gene Therapy
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateSep 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization under the medical benefit for Hemgenix and Roctavian before administration.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2Gene therapies requiring prior authorization
    One-timeApproved dosing approach

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    <1 IU/dL
    Factor VIII activity threshold
    AnnualHigh-risk liver monitoring
    Weekly x3 monthsHemgenix transaminase monitoring

    Coverage Criteria

    Hemophilia A — Roctavian

    Roctavian may be considered for coverage when ALL of the following criteria are met.

    Roctavian coverage eligibility

    • Confirmed diagnosis

      • ALL of the following

        • Chart notes document a confirmed diagnosis of severe hemophilia A due to hereditary factor VIII deficiency.Factor VIII activity <1 IU/dL
    • Required testing and assessments

      • No pre-existing antibodies to AAV5 are demonstrated using an FDA-approved companion diagnostic.
      • Factor VIII inhibitor titer testing is negative.
      • Liver function testing includes ALT, AST, GGT, ALP, total bilirubin, and INR.
      • An ultrasound or laboratory assessment for liver fibrosis has been performed.
    • Provider attestation and monitoring

      • The provider attests that evaluation for thrombosis and cardiovascular risk factors has been completed and will be monitored after Roctavian infusion.
      • For members with pre-existing risk factors for hepatocellular carcinogenicity—including cirrhosis, advanced hepatic fibrosis, hepatitis B or C, NAFLD, chronic alcohol consumption, NASH, or advanced age—regular annual liver ultrasound and alpha-fetoprotein testing will be performed following administration.

    Hemophilia B — Hemgenix

    Hemgenix may be considered for coverage when ALL of the following criteria are met.

    Hemgenix coverage eligibility

    • Chart notes document a confirmed diagnosis of moderately severe or severe hemophilia B due to hereditary factor IX deficiency.
    • Required inhibitor testing

      • Factor IX inhibitor titer testing is negative.
      • If the initial factor IX inhibitor test is positive, documentation shows repeat testing within 2 weeks.

        Applies when the initial test is positive.

    • Liver health assessment

      • Liver enzyme testing includes ALT, AST, ALP, and total bilirubin.

    Coverage is excluded for previous gene therapy treatment, a member who is biologically female, or use outside FDA-approved package labeling for the indication, age, dose, dosing frequency, or duration of therapy.

    Roctavian is excluded when the member has significant hepatic fibrosis at stage 3 or 4 on the Batts-Ludwig scale or equivalent, mannitol hypersensitivity, active or uncontrolled infection including chronic active hepatitis B, a positive AAV5 antibody test, or a positive factor VIII inhibitor test.

    Hemgenix is excluded for active hepatitis B or C infection, uncontrolled HIV infection, or positive results on both the initial and repeat tests for human factor IX inhibitors.

    Coding and Monitoring Requirements

    Drugs Requiring Prior Authorization under the medical benefitHCPCSCovered
    J1411Hemgenix (injection, etranacogene dezaparvovec-drlb)
    J1412Roctavian (injection, valoctocogene roxaparvovec)
    Factor VIII activity
    ThresholdFactor VIII activity <1 IU/dL
    ConditionSevere hemophilia A due to hereditary or congenital factor VIII deficiency
    UseThe threshold is used to determine eligibility for Roctavian coverage
    Repeat factor IX inhibitor testing
    Initial resultA positive factor IX inhibitor test requires repeat testing
    Repeat testing timeframeRetest within 2 weeks of the initial positive test
    Documentation

    Provider Actions and Authorization Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required under the medical benefit for Hemgenix and Roctavian before administration.

    • J1411 — Hemgenix (etranacogene dezaparvovec-drlb)
    • J1412 — Roctavian (valoctocogene roxaparvovec)
    Documentation Required

    Roctavian Clinical Documentation

    For Roctavian, submit current chart notes establishing the diagnosis and documenting all required laboratory, antibody, inhibitor, and liver assessments. Coverage is contingent on eligibility at the time of infusion.

    • Confirmed diagnosis of severe hemophilia A: hereditary factor VIII deficiency with factor VIII activity <1 IU/dL
    • No pre-existing antibodies to AAV5, demonstrated using an FDA-approved companion diagnostic

    Background

    Hemgenix and Roctavian are adeno-associated virus vector-based gene therapies for adults with inherited bleeding disorders. Hemgenix is used for hemophilia B caused by congenital factor IX deficiency, while Roctavian is used for severe hemophilia A caused by congenital factor VIII deficiency. Both therapies introduce a functional coagulation-factor gene intended to increase factor activity and improve hemostasis.

    Definitions

    AAV5
    DefinitionAAV5 is adeno-associated virus serotype 5
    Eligibility requirementRoctavian coverage requires no pre-existing antibodies to AAV5
    Testing methodAAV5 antibody status must be demonstrated using an FDA-approved companion diagnostic
    Severe hemophilia A
    DefinitionSevere hemophilia A is hereditary or congenital factor VIII deficiency
    Factor VIII activityFactor VIII activity must be below 1 IU/dL
    Policy useThis definition is used for Roctavian coverage eligibility

    Initial Authorization Criteria

    Roctavian initial authorization

    Roctavian may be considered for coverage when ALL of the following criteria are met.

    • Confirmed diagnosis

      • Chart notes document a confirmed diagnosis of severe hemophilia A due to hereditary factor VIII deficiency.Factor VIII activity <1 IU/dL
    • Current required testing and assessments

      • No pre-existing antibodies to AAV5 are demonstrated using an FDA-approved companion diagnostic.
      • Factor VIII inhibitor titer testing is negative.

    Quantity and Dosing Limits

    One-time dose limitation
    Roctavian limitRoctavian is approved as a one-time dose
    Hemgenix limitHemgenix is approved as a one-time dose
    Replacement productsRequests for replacement due to lost or damaged product are not covered
    Policy Summary
    PayerMVP Health Care
    PolicyMedicare Part B: Hemophilia Gene Therapy
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateSep 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization under the medical benefit for Hemgenix and Roctavian before administration.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Monitoring RequirementsProvider Actions and Authorization RequirementsBackgroundDefinitionsInitial Authorization CriteriaQuantity and Dosing Limits
  1. Hepatic ultrasound and elastography have been performed.
  2. ONE of the following bleeding or prophylaxis criteria

    • The member currently uses factor IX prophylaxis.
    • The member has a current or historical life-threatening hemorrhage.
    • The member has had repeated, serious spontaneous bleeding episodes.
  3. Provider attestation and monitoring

    • For members with pre-existing risk factors for hepatocellular carcinogenicity—including cirrhosis, advanced hepatic fibrosis, hepatitis B or C, NAFLD, chronic alcohol consumption, NASH, or advanced age—regular annual liver ultrasound and alpha-fetoprotein testing will be performed following administration.
    • Transaminase levels will be monitored once per week for 3 months and thereafter monthly up to 1 year after administration.
    • Factor IX activity levels will be monitored regularly after Hemgenix administration.
  4. Chart notes must document the repeat factor IX inhibitor testing
    Hemgenix transaminase monitoring
    Initial monitoringMonitor transaminase levels once per week for 3 months after Hemgenix administration
    Extended monitoringAfter the first 3 months, monitor monthly through 1 year after administration
    Additional monitoringFactor IX activity levels must also be monitored regularly after Hemgenix administration
  5. Negative factor VIII inhibitor titer testing
  6. Liver function tests: ALT, AST, GGT, ALP, total bilirubin, and INR
  7. Ultrasound or laboratory assessment for liver fibrosis
  8. Documentation Required

    Hemgenix Clinical Documentation

    For Hemgenix, submit current chart notes establishing the diagnosis and documenting required inhibitor, liver-health, and bleeding-history or prophylaxis evidence. Coverage is contingent on eligibility at the time of infusion.

    • Confirmed diagnosis of moderately severe or severe hemophilia B: hereditary factor IX deficiency
    • Negative factor IX inhibitor titer testing; if the initial test is positive, document repeat testing within 2 weeks
    • Liver-health assessments, including ALT, AST, ALP, total bilirubin, hepatic ultrasound, and elastography
    • Current Factor IX prophylaxis, or a current or historical life-threatening hemorrhage, or repeated serious spontaneous bleeding episodes
    Documentation Required

    Provider Attestation and Monitoring Plan

    The provider must attest that required risk evaluations and post-administration monitoring will be completed. Monitoring must address hepatocellular carcinogenicity risk when applicable and the product-specific laboratory and factor activity requirements.

    • Roctavian: attest that evaluation for thrombosis and cardiovascular risk factors is complete and will continue after infusion
    • For pre-existing hepatocellular carcinogenicity risk factors—cirrhosis, advanced hepatic fibrosis, hepatitis B or C, NAFLD, chronic alcohol consumption, NASH, or advanced age—perform annual liver ultrasound and alpha-fetoprotein testing after administration
    • Hemgenix: monitor transaminase levels weekly for 3 months, then monthly through 1 year; monitor Factor IX activity regularly
    • Hemgenix: for the same pre-existing hepatocellular carcinogenicity risk factors, perform annual liver ultrasound and alpha-fetoprotein testing after administration
    Denial Risk

    Failure to Meet Eligibility Criteria

    Authorization may be denied, or coverage may not continue, when required eligibility, clinical documentation, laboratory, provider-attestation, or monitoring requirements are not met.

    • Roctavian exclusions include significant hepatic fibrosis (Batts-Ludwig stage 3 or 4 or equivalent), mannitol hypersensitivity, active or uncontrolled infection including chronic active hepatitis B, positive AAV5 antibody testing, or positive factor VIII inhibitor testing
    • Hemgenix exclusions include active hepatitis B or C infection, uncontrolled HIV infection, or positive initial and repeat human factor IX inhibitor testing
    • Eligibility must be confirmed at the time of infusion; each product is approved as a one-time dose
    Denial Risk

    Lost or Damaged Product Not Covered

    Replacement requests for product that is lost or damaged are not covered.

    • Applies to Roctavian and Hemgenix
    • Both products are approved as one-time doses
    Denial Risk

    General Exclusion Conditions

    Coverage excludes use outside the policy and FDA-approved package-labeling requirements, as well as treatment following prior gene therapy or for biologically female members.

    • Previous gene therapy treatment
    • Member is biologically female
    • Indication, age, dose, frequency of dosing, or duration of therapy outside FDA-approved package labeling
    Hemophilia B
    DefinitionHemophilia B is hereditary or congenital factor IX deficiency
    SeverityThe policy recognizes moderately severe or severe hemophilia B
    Qualifying clinical historyCoverage criteria include current Factor IX prophylaxis, a current or historical life-threatening hemorrhage, or repeated serious spontaneous bleeding episodes
    Liver function testing includes ALT, AST, GGT, ALP, total bilirubin, and INR.
  9. An ultrasound or laboratory assessment for liver fibrosis has been performed.
  10. Provider attestation

    • The provider attests that evaluation for thrombosis and cardiovascular risk factors has been completed and will be monitored after Roctavian infusion.
    • For members with pre-existing risk factors for hepatocellular carcinogenicity—including cirrhosis, advanced hepatic fibrosis, hepatitis B or C, NAFLD, chronic alcohol consumption, NASH, or advanced age—regular annual liver ultrasound and alpha-fetoprotein testing will be performed following administration.
  11. Hemgenix initial authorization

    Hemgenix may be considered for coverage when ALL of the following criteria are met.

    • Chart notes document a confirmed diagnosis of moderately severe or severe hemophilia B due to hereditary factor IX deficiency.
    • Factor IX inhibitor testing

      • Factor IX inhibitor titer testing is negative.
      • If the initial factor IX inhibitor test is positive, documentation shows repeat testing within 2 weeks.

        Applies when the initial test is positive.

    • Liver health assessments

      • Liver enzyme testing includes ALT, AST, ALP, and total bilirubin.
      • Hepatic ultrasound and elastography have been performed.
    • ONE of the following bleeding or prophylaxis criteria

      • The member currently uses factor IX prophylaxis.
      • The member has a current or historical life-threatening hemorrhage.
      • The member has had repeated, serious spontaneous bleeding episodes.
    • Provider attestation and monitoring

      • For members with pre-existing risk factors for hepatocellular carcinogenicity—including cirrhosis, advanced hepatic fibrosis, hepatitis B or C, NAFLD, chronic alcohol consumption, NASH, or advanced age—regular annual liver ultrasound and alpha-fetoprotein testing will be performed following administration.
      • Transaminase levels will be monitored once per week for 3 months and thereafter monthly up to 1 year after administration.
      • Factor IX activity levels will be monitored regularly after Hemgenix administration.